

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMPLETION OF FILING NATIONAL PHASE OF PCT APPLICATION
UNDER RULE 35 USC 371 AND 37 CFR 1.494(C) OR 1.495(C)

#3

BOX PCT**COMPLETION**
For PCT Cases OnlyIn re PATENT APPLICATION of
Inventor(s): James P. Burnie et al.

Attn: Application Division

Appln. No.: 09 | 889,314
Series Code ↑ Serial No. ↑Atty. Dkt. P 0281578 |
M# Client Ref

National Phase Field

Based on PCT GB00 | 00237
↑ Country Code & Year

Title: MEDICAMENT

Date: November 20, 2001

FILING OF ITEM(S) LATE IN PCT/USA NATIONAL CASEAsst. Commissioner of Patents
Washington, DC 20231

Sir:

The following completes the filing of the subject application under Rule 494(c)/495(c). Please accept the following attached items:

1. Missing Requirements Notice (PCT/DO/EO/905) ☒ copy attached ☐ not yet received
2. ☒ **Signed Declaration** ☒ Original ☐ Facsimile/Copy ☐ with spec/claims attached
3. ☐ **Translation** of the International Application into English including:
 - a. ☐ Request;
 - b. ☐ Abstract
 - c. ☐ pgs. Spec. and Claims;
 - d. ☐ Translation verification
 - e. ☐ sheets Drawing which are: ☐ informal ☐ formal of size ☐ A4 ☐ 11"
4. ☐ Copy of **International Search Report (ISR)** attached (☐ page(s))
 - a. ☐ plus Annex of family members (☐ page(s))
5. **Information Disclosure Statement** including
 - a. ☐ From PTO-1449 listing documents
 - b. ☐ Copies of document(s) listed on Form PTO-1449
 - c. ☐ A concise explanation of ISR references is given in the ISR
6. ☒ **Assignment** and cover sheet. Please return the recorded assignment to the undersigned.
7. ☐ Copy of Power to international application agent.
8. 2 (No.) Small Entity Statement(s) establishing "small entity" status under Rules 9 & 27.
9. ☐ Formal Drawings: ☐ sheet(s) ☐ informal; ☐ formal of size: ☐ A4 ☐ 11"
10. ☒ Please immediately start national examination procedures (35 USC 371(f))

11. ☒ Attached: Sequence Listing with computer readable copy
12. ☐ Preliminary Amendment:
13. ☒ Basic U.S. National fee per Rule 492(a)(1)-(4) was previously timely filed.:
14. **Calculation of remaining fees due (if any):** based on amended claim(s) per above item
☐ 12 (above) or item(s) in PAT-112 (filed previously) ☐ 12 ☐ 14 ☐ 17 ☐ 25
15. **CLAIMS FEES** ☒ previously paid ☐ paid herewith as follows:
- 15A. Small Entity Statement ☒ Herewith ☐ Previously Filed

				Large/Small Entity		Fee Code
16. Total Effective Claims		minus 20 =		x \$18/\$9	+	966/967
17. Independent Claims		minus 3 =		x \$84/\$42	+	964/965
18. If <u>any proper</u> multiple dependent claim (ignore improper) is present,				\$280/\$140	+	968/969
19. Filing Declaration late, fee paid <input type="checkbox"/> previously <input checked="" type="checkbox"/> now				\$130/\$65	+65	154/254
20. SUBTOTAL					\$65	
21. Original due date: October 23, 2001						
22. Petition is hereby made to extend the original due date to				(1 mo)	\$110/\$55 =	+55
cover the date this response is filed for which the requisite fee				(2mos)	\$400/\$200 =	115/215
is attached				(3mos)	\$920/\$460 =	116/216
				(4mos)	\$1,440/\$720 =	117/217
23. If "non-English" box 3 is X'd, add Rule 17(k) processing fee				\$130	+0	118/218
24. If "assignment" box 6 is X'd, add recording fee.				\$40	+40	156
25. TOTAL FEE ENCLOSED =					\$160	581

(Our Deposit Account No. 03-3975)

(Our Order No. 050885 | 0281578)
C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

Pillsbury Winthrop LLP
Intellectual Property Group

1600 Tysons Boulevard
McLean, VA 22102
Tel: (703) 905-2000

By Atty: Bonnie Weiss McLeod

Reg. No. 43,255

Sig: Bonnie W. McLeod

Fax: (703) 905-2500

Tel: (703) 905-2219

BWM/kmh

NOTE: File in duplicate with PTO receipt (PAT-103A) and attachments

11/21/2001 LLANDGRA 00000020 09889314

01 FC:254 65.00 DP
02 FC:215 55.00 OP

Rec'd PCT/PTO 20 NOV 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

BOX SEQUENCE

James P. Burnie et al.

Group Art Unit: Unassigned

Application No. 09/889,314

Examiner: Unassigned

Filed: July 16, 2001

Title: MEDICAMENT

* * * * *

RESPONSE WITH SEQUENCE LISTING


Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated August 23, 2001, attached please find a copy of the "Sequence Listing" in computer readable format along with a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §1.821-1.825.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 
Bonnie Weiss McLeod
Registration No. 43,255

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: November 20, 2001

Enclosure: Statement to Support Filing
Sequence Listing (including electronic copy)



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/889314	BURNIE J	P0281578
INTERNATIONAL APPLICATION NO.		
PCT/GB00/00237		
I.A. FILING DATE	PRIORITY DATE	
28 JAN 00	05 FEB 99	
DATE MAILED: 23 AUG 2001		

PILLSBURY WINTHROP LLP
1600 TYSONS BOULEVARD
MCLEAN, VA 22102

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☒ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Barbara A. Campbell
Telephone: 703-305-3631